| Monoclonal antibody | |
|---|---|
| Type | Fab' fragment |
| Source | Mouse |
| Target | NCA-90 (granulocyte cell antigen) |
| Clinical data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| | |
Technetium (99mTc) sulesomab (trade nameLeukoScan) is a radio-pharmaceutical composed of anti-humanmousemonoclonal antibody[1] that targets the granulocyte associated NCA-90 cell antigen and a conjugatedtechnetium-99mradionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation bygamma camera imaging of99mTc-antibody bound cells.[2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation[3]
It is approved in European markets for the imaging ofinfections andinflammations in patients with suspectedosteomyelitis[4][5] but has not secured FDA approval for use in American markets.[6] In addition to approved uses, LeukoScan is currently being investigated for other diagnostic purposes like the detection ofsoft tissue infections, malignant external otitis and prosthetic joint infection.[7][8][9] However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent companyImmunomedics was discontinued in 2018.[10]
Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |